# US 10,501,802 B2 · Biomarkers for acute myeloid leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,802 B2
- Document ID: US10501802B2
- Status: Granted
- Kind: B2
- Application number: 14/888,108
- Filed: 2014-04-30
- Published: 2016-03-03
- Granted: 2019-12-10
- Earliest claimed: 2013-04-30
- Assignees: Universite de Montreal; Universite Laval
- Applicants: Universite De Montreal; Universite Laval
- Inventors: Brian Thomas Wilhelm; Frederic Barabe
- Web page: https://patentgrep.com/patent/US10501802B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/02: specific for leukemia
- C07K 16/18: against material from animals or humans
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/40: against enzymes
- G01N 33/57505: of the blood, e.g. leukaemia
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for the diagnosis of leukemias, and more specifically AML, such as MLL-AF9 AML, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in Tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of AML leukemic cells for treating AML is also disclosed.

## Claims

### Claim 1

A method for treating acute myeloid leukemia (AML) involving translocation of the mixed-lineage leukemia (MLL) gene in a subject, said method comprising administering to said subject an effective amount of a monoclonal antibody or an antigen-binding fragment thereof that binds to one or more of the following proteins: RET and CD70.

### Claim 2 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof binds to RET.

### Claim 3 (depends on 1)

The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof binds to CD70.